Dommasch ED, et al. - In this observational comparative cohort study of 107,707 individuals carried out using medical and outpatient pharmacy claims from two big US health insurance claims databases (the Optum Clinformatics Data Mart [n = 31,595] and the Truven MarketScan [n = 76,112]) from January 1, 2003, through September 30, 2015, researchers contrasted the risk of severe infection related to biologic and nonbiologic systemic medications in individuals with psoriasis, who were new users of systemic medications for psoriasis (ie, acitretin, adalimumab, apremilast, etanercept, infliximab, methotrexate, or ustekinumab). In two large US claims databases, among individuals with psoriasis treated with systemic medications, a reduced rate of severe infection was discovered in new users of apremilast, etanercept, and ustekinumab, in comparison with methotrexate.